Sternocostoclavicular hyperostosis (SCCH) is a disorder of unknown etiology and pathogenesis with various clinical and laboratory features such as hyperossification of soft tissues, hyperostosis in the area between the clavicles and upper ribs, pustular eruptions on the palms and soles and hyperimmunoglobulinemia [1] [2] [3] [4] [5] [6] [7] [8] [9] . From our clinical studies, we reported that the serum biotin levels in psoriasis vulgaris and pustulosis palmaris et plantaris patients were significantly less than those in normal subjects [10] . We tried biotin treatment of patients with these syndromes and obtained successful results; i.e., 70% (35/50) of the patients with psoriasis vulgaris and 57% (17/39) of those with pustulosis palmaris et plantaris showed an improvement of their dermatitis [10] . We also observed that osteogenic disorder Shionogi (ODS) rats fed a biotin-deficient diet containing raw egg white and sufficient ascorbic acid were afflicted with bone abnormalities, including a hunch in their vertebral column. They also had a significantly lower level of ascorbic acid in the plasma and liver than control rats [11] .
Biotin serves as a prosthetic group of the carboxylases, four of which occur in animal and human tissues [12, 13] . There are acetyl-CoA carboxylase involved in fatty acid synthesis, pyruvate carboxylase involved in glucose metabolism, and propionyl-CoA carboxylase and f3-methylcrotonyl-CoA carboxylase involved in the catabolism of amino acids. Biotin depletion, therefore, causes metabolic abnormalities such as an impairment of glucose utilization [14] [15] [16] , a reduced synthesis of prostaglandins (PGs) [17] and of their precursor fatty acids [18] [19] [20] [21] , and an accumulation of abnormal catabolites derived from amino acids [22, 23] . However, no information is available concerning the effect of biotin depletion on these metabolic abnormalities in patients with SCCH, nor is it known whether the metabolic abnormalities are associated with the pathogenesis of the disorder. Therefore, we undertook the present study to elucidate in greater detail the effect of biotin treatment on the metabolic abnormalities occurring in SCCH patients. SUBJECTS 
AND METHODS
Patients. Thirty patients with SCCH, 16 males and 14 females, 29-60 years of age (mean, 43 years), were recruited for the present study. The diagnosis was established dermatologically and orthopedically. The patients had been treated orally with non-steroidal anti-inflammatory drugs and topically with steroid ointments for more than 10 years with no benefit to their clinical, laboratory, and radiographic features. The patients had no clinical or laboratory evidence of hepatic diseases. The patients were instructed to maintain their ordinary diet but not to take any medication for at least 4 weeks prior to the study. As a control, 20 healthy subjects, 10 males and 10 females, volunteered for the study. None of the subjects had any significant past history or any family history of diabetes mellitus. None of the patients or subjects were obese, being within 14% of ideal weight based upon the Broca index.
Oral administration of biotin. The patients were treated with a combination of biotin, 9 mg daily, and an antimicrobial drug, Miya-BM's (Miyarisan Pharmaceutical Co., Tokyo), 3 g daily, each given in three divided doses. The use of the antimicrobial drug was aimed to prevent the proliferation of `toxic' intestinal microflora that might digest or degrade the administered biotin. The purpose of this study was explained to all patients and their consent was obtained before the start of the study.
Analytical procedures. Blood sampling was performed in the morning after Tokyo). The relative concentration of the individual FA was expressed as a percentage of the total concentrations of these FAs. Serum amino acids were analyzed with an amino acid autoanalyzer (JLC-10, D-type, Nihon Denshi, Tokyo) after deproteinization of the serum with 10% trichloroacetic acid. The serum biotin level was measured microbiologically. The test organism was Lactobacillus plantarum (ATCC 8014). The preparation of the samples from the serum was done as described previously [11] . The blood glucose level was estimated by standard glucose oxidase methodology (Glucose C-test Wako, Wako Pure Chemical, Osaka). The plasma ascorbic acid concentration was quantified by the o-phenylenediamine fluorescence method after deproteinization with 8% acetic acid solution containing 3% metaphosphoric acid [24] . Urinary excretion of hydroxyproline was estimated fluorometrically with p-dimethylaminobenzaldehyde [25] .
Statistical analysis. All results are expressed as mean ± SEM. Statistical analysis was performed by the two-tailed Student's t-test for paired and unpaired data, with p <0.05 accepted as the level of significance.
RESULTS

Clinical observations
The chest radiograph of a patient with SCCH ( Fig. 1(a) ) showed advanced bone lesions in both clavicles and first ribs with severe osseous hypertrophy and sclerotic change. Interspaces between the clavicles and the first ribs were completely fused with abnormal ossification. One year after the treatment with biotin, however, the bone lesions improved; and the contours and matrix shadows of the bones became visible, though slight hypertrophy was still seen (Fig. 1(b) ). Figure  2 (a) shows skin lesions on the palm of another patient before the administration of biotin. The pustular eruptions were evident. Two months after the start of treatment, the eruptions were almost corrected ( Fig. 2(b) ).
Serum biotin and amino acids
Before the treatment, the serum biotin level was significantly low in the patients (36.5 + 12.3 nmol/liter) as compared with that in the normal subjects (90.7+ 14.3 nmol/liter). Table 1 lists the levels of serum amino acids in the patients in comparison with those in the normal subjects. As shown in the table, threonine, serine, glutamic acid, glutamine, proline, valine, isoleucine, and leucine were elevated in the patients. The treatment decreased these amino acids levels, except for proline, to normal ranges within 2 months.
Serum fatty acids
The results of the fatty acid analysis are summarized in Tables 2, 3 , and 4. For serum phospholipids (Table 2) , the levels of linoleic acid (18:2n-6) and a-linolenic acid (18:3n-3) tended to be high in the patients as compared with those in the controls. On the contrary, the levels of arachidonic acid (20:4n-6) were significantly lower in the patients, and those of eicosapentaenoic acid (20:5n-3), docosapentaenoic acid (22:5n-6), and docosahexaenoic acid (22:6n-3) tended to be low in the patients. The ratios of 20:4n-6/18:2n-6 and 20:5n-3/18:3n-3 were significantly lower by approximately one-half and one-third, respectively, in the patients compared with those of the controls. In the case of serum triglycerides (Table 3) , the levels of 22:5n-6 and 22:6n-3 were significantly lower in the patients as compared with those in the controls. However, all other fatty acids mentioned above were not significantly different in level between the groups. After the treatment, these abnormal profiles mentioned above were corrected to normal within 2 months. There was no significant difference in fatty acid profiles in serum cholesterol esters between the patients and the controls (Table 4 ). Values are means ± SEM. Significant differences are indicated by * p <0.05, * * p <0.01, * * *p <0 .001 with respect to the corresponding control (normal subject value).
Blood glucose and other substances
Seven patients had a fasting blood glucose level greater than 8.3 mmol/liter before the treatment. Four of the remaining patients showed a diabetic pattern in response to a 75-g oral glucose load, although their fasting blood glucose level was within the normal range. The biotin treatment improved the hyperglycemia and Values are expressed as the percentage of the sum of the concentrations of measured fatty acids (means ± SEM). Significant differences are indicated by * p<0.05 and **p<0•01 with respect to the corresponding control (normal subject values). Table 3 . Effect of biotin on fatty acid levels in serum triglycerides.
Values are expressed as the percentage of the sum of the concentrations of measured fatty acids (means ± SEM). Significant differences are indicated by **p <0.01 with respect to the corresponding control (normal subject values). normalized the glucose tolerance within 2 months (data not shown). The plasma ascorbic acid concentration tended to be low in the patients as compared with that in the controls before the treatment, but increased towards normal 2 months after the start of treatment (Table 5 ). Urinary excretion of hydroxyproline was determined in 10 patients before and 2 months after the start of treatment. The treatment decreased the excretion to the normal range. Creatinine excretion was unchanged within normal range (Table 6 ).
DISCUSSION
The present study demonstrated low serum biotin levels in patients with
SCCH.
The study also showed hyperglycemia and abnormal profiles of serum Values are expressed as the percentage of the sum of the concentrations of measured fatty acids (means±SEM). Table 5 . Effect of biotin on plasma ascorbic acid level.
Values are means+SEM. amino acids and fatty acids in the patients. Biotin is required for the catabolic processing of branched-chain amino acids, which degradation is catalyzed by propionyl-CoA carboxylase and f3-methylcrotonyl-CoA carboxylase [12, 13] . It is, therefore, presumed that biotin depletion in the patients may interfere with amino acid catabolism as a consequence of reduced activities of these enzymes, creating altered profiles of serum amino acids. In support of this hypothesis, biotin treatment corrected the abnormal amino acid profiles. The patients had abnormal fatty acid spectra in serum lipids, particularly in PLs: tendency toward increased linoleic acid and a significant decrease in its major metabolite, arachidonic acid. The ratios of 20:4n-6/ 18:2n-6 and 20:5n-3/18:3n-3 in serum PLs were significantly lower in the patients than in the controls. The dysfunction of acetyl-CoA carboxylase due to biotin depletion may impair the elongation of linoleic acid to arachidonic acid and of a-linolenic acid to eicosapentaenoic acid, resulting in altered an FA spectrum. Experimentally it has been shown that the n-6 fatty acid abnormalities are reproduced in biotin-deficient chicks and rats, and are reversed after supplementation with the vitamin [17] [18] [19] [20] [21] [22] [23] 26] . The changes in the FA spectrum induced by biotin treatment are likely to have many desirable consequences, particularly in the metabolism of PG synthesis [27, 28] . PGs, oxygenation products of FAs, may act via several mechanisms: PGE1 has an anti-inflammatory property through its ability to regulate the generation of arachidonic acid, and PGE2 may improve the capacity of the immune system to regulate T-and B-lymphocytic interactions [29] . Another mechanism worthy of further consideration regarding low FA levels in PLs is the integrity of the skin and bone formation, because the FAs are the most important structural components of fibroblasts and osteoblasts and modulate the replication and differentiation of the cells [30] [31] [32] . Additional demonstration of impaired glucose metabolism in the patients may provide further documentation of the reduced activity of pyruvate carboxylase, which enzyme plays a key role in glucose utilization via entry of pyruvate into the tricarboxylic acid cycle and whose reduced activity leads to hyperglycemia. Biotin has been reported to enhance guanylate cyclase activity thus increasing cGMP level in rat liver [33] . Li Hsieh and Mistry [34] demonstrated that biotin restored glucokinase activity by stimulating the synthesis of the enzyme by increasing the cGMP level in rats. In 11 patients in the present study, hyperglycemia and abnormal glucose tolerance were observed. Biotin treatment, however, improved these abnormalities, irrespective of the serum insulin profile, perhaps by enhancing the enzyme activities of pyruvate carboxylase or glucokinase and subsequent utilization of glucose. We previously observed that ODS rats fed a biotin-deficient diet were afflicted with bone abnormalities and had a significantly lower level of ascorbic acid in their plasma and liver than control rats [11] . The reduction in the ascorbic acid level may promote ascorbic acid consumption in the organs of biotin-deficient rats. Although the details of the biochemical mechanism for the action of ascorbic acid remains uncertain, ascorbic acid is required for the hydroxylation of proline in collagen biosynthesis [35, 36] . In this study, increased urinary excretion of hydroxyproline and a tendency toward a depletion of serum ascorbic acid in the patients were observed. The hydroxyproline excretion is considered to reflect many of the clinical manifestations associated with faulty changes in collagen metabolism [25, 37, 38] . Moreover, ascorbic acid depletion may directly affect the immunoregulatory function, perhaps by mediating its effect on the proliferation and/or the function of lymphocytes through increasing the cGMP level [39] [40] [41] .
The present results suggest that the metabolic abnormalities due to biotin depletion are implicated in the pathogenesis of SCCH and that the correction of these abnormalities by biotin treatment is effective in the therapy of the patients.
